SCHEMBL25288602

SCHEMBL25288602

CN(c1ccncc1N)S(C)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
MEN1 O00255 2/20 0.42
KDM6B O15054 1/20 0.42
KDM4A O75164 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
KDM4D Q6B0I6 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GAA P10253 2/20 0.38
GLA P06280 1/20 0.38
CA12 O43570 3/20 0.37
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA9 Q16790 3/20 0.37
CA14 Q9ULX7 2/20 0.37
AOC1 P19801 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29740091 1.00 KMT2A (0.42) KMT2AKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL24497562 0.80 L3MBTL1 (0.38) KMT2AL3MBTL1MEN1TDP1HSD17B10
SCHEMBL21048846 0.78 AOC3 (0.41) KMT2AL3MBTL1MEN1AOC1AOC3
SCHEMBL11595840 0.77 AOC1 (0.43) KMT2AKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL29469204 0.77 AOC1 (0.43) KMT2AKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL24497527 0.76 L3MBTL1 (0.35) KMT2AL3MBTL1MEN1CA12CA1
SCHEMBL12672894 0.76 CA12 (0.46) KMT2AALDH1A1CA12CA1CA2
SCHEMBL19957625 0.75 AOC1 (0.42) KMT2AKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL29127185 0.74 AOC1 (0.42) KMT2AKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL3860689 0.73 TDP1 (0.47) KMT2AKDM4EALDH1A1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) 2024-03-28 US disclosed
EP-4257587-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2023-10-11 EP disclosed
EP-4206196-A1 PYRIMIDINE SUBSTITUTED DERIVATIVES AS TYK2 INHIBITORS Almirall S.A. (ES) 2023-07-05 EP disclosed
CN-116283954-A Hydroxamate compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-06-23 CN disclosed
CN-114901656-B Hydroximic acid ester compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2023-04-07 CN disclosed
CN-114901656-A Hydroximic acid ester compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2022-08-12 CN disclosed
WO-2022117016-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳微芯生物科技股份有限公司 2022-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101548-A1 HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TYK2, WEE2, WEE1 KMT2A 366/4885KDM4E 1202/4885ALDH1A1 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.